awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q37653125-3CA17FB6-DBDB-4235-8720-A068C3A669A8
Q37653125-3CA17FB6-DBDB-4235-8720-A068C3A669A8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37653125-3CA17FB6-DBDB-4235-8720-A068C3A669A8
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
P2860
Q37653125-3CA17FB6-DBDB-4235-8720-A068C3A669A8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37653125-3CA17FB6-DBDB-4235-8720-A068C3A669A8
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0d33e13623913dc1dd4625e7d101286db81a08d8
P2860
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment.